How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? – the good, the bad, and the ugly ways

References

• Organisation for Economic Co-operation and Development: OECD Health Statistics. 2017 [cited 2019 May 16]. DOI:10.1787/888933602405
   Google Scholar
• Elek P, Harsányi A, Zelei T, et al. Policy objective of generic medicines from the investment perspective: the case of clopidogrel. Health Policy. 2017;121(5):558–565.
   PubMed Web of Science ®Google Scholar
• Jönsson B, Hofmarcher T, Lindgren P, et al. Comparator report on patient access to cancer medicines in Europe revisited. IHE Rep. 2016;4:228.
   Google Scholar
• Kobelt G, Kasteng F. Access to innovative treatments in rheumatoid arthritis in Europe. European Federation of Pharmaceutical Industry Associations (EFPIA). 2009 [cited 2019 Nov 11]. Available from: http://www.comparatorreports.se/Access%20to%20RA%20Treatments%20October%202009.pdf
   Google Scholar
• Orlewska E, Ancuta I, Anic B, et al. Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries. Med Sci Monit. 2011;17(4):SR1–13.
   PubMed Web of Science ®Google Scholar
• Kostic M, Djakovic L, Šujić R, et al. Inflammatory bowel diseases: cost of treatment in Serbia and the implications. Appl Health Econ Health Policy. 2017;15:85–93.
   PubMed Web of Science ®Google Scholar
• Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73:198–206.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Misery L, Naeyaert S, et al. Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities? Front Pharmacol. 2019;10:279.
   PubMed Web of Science ®Google Scholar
• Simoens S, Picavet E, Dooms M, et al. Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum. Appl Health Econ Health Policy. 2013;11:1–3.
   PubMedGoogle Scholar
• Kaló Z, Annemans L, Garrison LP. Differential pricing of new pharmaceuticals in lower income European countries. Expert Rev Pharmacoecon Outcomes Res. 2013;13(6):6735–6741.
   Web of Science ®Google Scholar
• Kanavos PG, Vandoros S. Determinants of branded prescription medicine prices in OECD countries. Health Econ Policy Law. 2011;6(3):337–367.
   PubMed Web of Science ®Google Scholar
• Elek P, Takács E, Merész G, et al. Implication of external price referencing and parallel trade on pharmaceutical expenditure: indirect evidence from lower-income European countries. Health Policy Plan. 2017;32(3):349–358.
   PubMed Web of Science ®Google Scholar
• Kaló Z, Landa K, Doležal T, et al. Transferability of national institute for health and clinical excellence recommendations for pharmaceutical therapies in oncology to Central-Eastern European countries. Eur J Cancer Care. 2012;21(4):442–449.
   PubMed Web of Science ®Google Scholar
• Radu CP, Chiriac ND, Pravat AM. The development of the romanian scorecard HTA system. Value Health Reg Issues. 2016;10:41–47.
   PubMedGoogle Scholar
• Kwong D, Ferrario A, Adamski J, et al. Managing the introduction of new and high-cost drugs in challenging times: the experience of Hungary and Poland. Eurohealth Incorporating Euro Observer. 2014;20:25–28.
   Google Scholar
• Malmstrom RE, Godman BB, Diogene E, et al. Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol. 2013;4:39.
   PubMed Web of Science ®Google Scholar
• Inotai A, Kaló Z. Risk sharing methods in middle income countries. Acta Pharm Hung. 2012;82(1):43–52.
   PubMedGoogle Scholar
• Gonçalves FR, Santos S, Silva C, et al. Risk-sharing agreements, present and future. Ecancermedicalscience. 2018;12:823.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Patient Access Schemes Liaison Unit. [cited 2019 Aug 6]. Available from: https://www.nice.org.uk/Media/Default/About/what-we-do/PASLU/NICE-recommended-technologies-that-include-a-commercial-arrangement.xlsx
   Google Scholar
• Garattini L, Curto A, van de Vooren K. Italian risk-sharing agreements on drugs: are they worthwhile? Eur J Health Econ. 2015;16(1):1–3.
   PubMed Web of Science ®Google Scholar
• Adamski J, Godman B, Ofierska-Sujkowska G, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res. 2010;10:153.
   PubMed Web of Science ®Google Scholar
• Ferrario A, Arāja D, Bochenek T. The implementation of managed entry agreements in Central and Eastern Europe: findings and implications. Pharmacoeconomics. 2017;35(12):1271–1285.
   PubMed Web of Science ®Google Scholar
• Kaló Z, Gheorghe A, Huic M, et al. HTA implementation roadmap in Central and Eastern European countries. Health Econ. 2016;25(Suppl 1):179–192.
   PubMed Web of Science ®Google Scholar
• Inotai A, Csanádi M, Vitezic D, et al. Policy practices to maximise social benefit from biosimilars. J Bioequivalence Bioavailability. 2017;9:467–472.
   Google Scholar
• Tran G, Zafar SY. Financial toxicity and implications for cancer care in the era of molecular and immune therapies. Ann Transl Med. 2018;6(9):166.
   PubMed Web of Science ®Google Scholar
• Inotai A, Csanadi M, Petrova G, et al. Patient access, unmet medical need, expected benefits, and concerns related to the utilisation of biosimilars in eastern european countries: a survey of experts. Biomed Res Int. 2018;10:9597362.
   Google Scholar
• Kaló Z, Holtorf AP, Alfonso-Cristancho R, et al. Need for multicriteria evaluation of generic drug policies. Value Health. 2015;18:346–351.
   PubMed Web of Science ®Google Scholar
• Leporowski A, Godman B, Kurdi A, et al. Ongoing activities to optimize the quality and efficiency of lipid-lowering agents in the Scottish national health service: influence and implications. Expert Rev Pharmacoecon Outcomes Res. 2018;18:655–666.
   PubMed Web of Science ®Google Scholar
• Garuoliene K, Godman B, Gulbinovič J, et al. Differences in utilization rates between commercial and administrative databases: implications for future health-economic and cross-national studies. Expert Rev Pharmacoecon Outcomes Res. 2016;16:149–152.
   PubMed Web of Science ®Google Scholar
• Markovic-Pekovic V, Skrbić R, Godman B, et al. Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions. Expert Rev Pharmacoecon Outcomes Res. 2012;12:661–671.
   PubMed Web of Science ®Google Scholar
• Kaló Z, Vokó Z, Östör A, et al. Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region. J Mark Access Health Policy. 2017;5(1):1345580.
   PubMedGoogle Scholar
• Zhai MZ, Sarpatwari A, Kesselheim AS. Why are biosimilars not living up to their promise in the US? AMA J Ethics. 2019;21(8):E668–78.
   PubMedGoogle Scholar
• Harsányi A, Csanádi M, Márky K, et al. Biosimilar infliximab utilization after patent expiry: the case of colitis ulcerosa and rheumatoid arthritis. Value Health. 2018;21:S95–6.
   PubMed Web of Science ®Google Scholar
• Harsányi A, Csanádi M, Marky K, et al. Utilization and switching patterns of biological medicines in the indications of infliximab before and after patient expiry. Value Health. 2019;22:S51.
   Web of Science ®Google Scholar
• Harsányi A, Csanádi M, Márky K, et al. Influence of biosimilar infliximab launch on the utilization pattern of biological medicines: the case of Hungary. Expert Rev Pharmacoecon Outcomes Res. 2019. DOI:10.1080/14737167.2019.1667232.
   PubMed Web of Science ®Google Scholar
• Dylst P, Vulto A, Simoens S. Barriers to the uptake of biosimilars and possible solutions: a Belgian case study. Pharmacoeconomics. 2014;32(7):681–691.
   PubMed Web of Science ®Google Scholar
• Yang YT, Chen B, Bennett CL. Biosimilars — curb your enthusiasm. JAMA Oncol. 2017;3:1467–1468.
   PubMed Web of Science ®Google Scholar
• Frank RG. Friction in the path to use of biosimilar drugs. N Engl J Med. 2018;378:791–793.
   PubMedGoogle Scholar
• Inotai A, Ágh T, Karpenko AW, et al. Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries. Expert Rev Pharmacoecon Outcomes Res. 2019;19(2):105–113.
   PubMed Web of Science ®Google Scholar
• Chen B, Yang YT, Bennett C. Friction in the Path to Use of biosimilar drugs. N Engl J Med (Letter). 2018;378(22):2148.
   PubMedGoogle Scholar
• Chen B, Yang YT, Bennett CL. Challenges to biosimilar substitution (Letter). JAMA. 2017;318:1186.
   PubMed Web of Science ®Google Scholar
• Hakim A, Ross JS. Obstacles to the adoption of biosimilars for chronic diseases. JAMA. 2017;317:2163–2164.
   PubMed Web of Science ®Google Scholar
• Moorkens E, Vulto AG, Huys I, et al. Policies for biosimilar uptake in Europe: an overview. PLoS One. 2017;12(12):e0190147.
   PubMed Web of Science ®Google Scholar